ACRP Exam QUESTIONS AND ANSWERS GRADED A LATEST 2023/2024 COMPLETE SOLUTION
1 view 0 purchase
Course
ACRP
Institution
ACRP
ACRP Exam QUESTIONS AND
ANSWERS GRADED A LATEST
2023/2024 COMPLETE SOLUTION
What individual serves as the primary liaison between the sponsor and the
investigator? - CORRECT ANSWER monitor
Who is responsible for verifying that the investigator follows the approved
protocol and all approve...
ACRP Exam QUESTIONS AND
ANSWERS GRADED A LAEST 2023/2024
What individual serves as the primary liaison between the
sponsor and the investigator? - CORRECT ANSWER monitor
Who is responsible for verifying that the investigator follows the
approved protocol and all approved amendments? - CORRECT
ANSWER monitor
Who must be notified if a trial is suspended or terminated
prematurely? - CORRECT ANSWER the sponsor should
promptly inform the investigator/institutions and the regulatory
authorities of the termination or suspension and the reasons for
the termination or suspension
Who must the monitor inform of CRF entry errors, omissions, or
illegibly? - CORRECT ANSWER investigator
factoral design - CORRECT ANSWER Used for the specific
purpose of examining interaction of A and B; 2 or more treatments
are evaluated simultaneously through the use of varying
combinations of the treatments
1. A alone
2. B alone
3. both A & B (useful in determining joint effects of A & B)
4. neither A or B
*another important use of the design is to establish the dose-
response characteristics of the simultaneous use of treatments C
&D
,What are the purposes of multi center trials? - CORRECT
ANSWER 1. an accepted way of evaluating a new medication
more efficiently; may present as the only practical means of
accruing sufficient subjects to satisfy the trial objective within a
reasonable time-frame
2. to provide a better bias for the subsequent generalization of its
findings
phase I (human pharmacology) - CORRECT ANSWER
SAFETY; starts with the initial administration of an investigational
new drug into humans; small # of study subjects 20-80
aspects of phase 1 trials
- to determine the tolerability of the dose range expected to be
needed for later clinical studies and to determine the nature of
adverse reactions that can be expected
- characterization of a drug's absorption, distribution, metabolism,
and excretion continues throughout the development plan
-pharmacodynamic studies and studies relating drug blood levels
to response (PK/PD studies) may be conducted healthy volunteer
subjects or in patients with the target disease
phase II (therapeutic exploratory) - CORRECT ANSWER
EFFICACY; the primary objective is to explore therapeutic
efficacy in patients; studies are typically conducted in a group of
patients who are selected by relatively narrow criteria, leading to a
relatively homogenous population and are closely monitored;
early studies often utilize dose escalation designs; several 100
subjects
goal
- determine the dose(s) and regimen for phase III trials
- include evaluation of potential study endpoints, therapeutic
regimens, and target populations
, - determine short term side effects and risks associated with the
drug
phase III (therapeutic confirmatory) - CORRECT ANSWER
LONG-TERM SAFETY/SURVIVAL; primary objective is to
demonstrate, or confirm therapeutic benefit; designed to confirm
the preliminary evidence accumulated in phase II that a drug is
safe and effective for use in the intended indication and recipient
population; they complete the information needed to support
adequate instructions for use of the drug (official product
information); several 100 - 1000's of subjects
studies may further explore the dose-response relationship, or
explore the drug's use in wider populations, in different stages of
disease, or in combination with another drug
*end of phase III is when NDA is sent to the FDA for approval
phase IV (therapeutic use) - CORRECT ANSWER POST
MARKET; begins after drug approval; are all studies (other than
routine surveillance) performed after drug approval and related to
the approved indication; address FDA requirements for additional
information not in NDA
commonly conducted studies include additional drug-drug
interaction, dose-response or safety studies, and studies
designed to support use under the approved indication, e.g.
mortality/morbidity studies, epidemiological studies
adverse event - CORRECT ANSWER any untoward medical
occurrence in a patient or clinical investigation subject
administered a pharmaceutical product and which does not
necessarily have to have a causal relationship with this treatment
e.g. abnormal laboratory finding, symptom, or disease
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller GREATSTUDY. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $12.49. You're not tied to anything after your purchase.
